Investors of Aardvark Therapeutics Face Class Action Lawsuit Due to Significant Losses

The legal landscape is becoming increasingly daunting for investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD). Those who have experienced substantial financial setbacks are now presented with an opportunity to lead a class action lawsuit against the biopharmaceutical company, with a pressing key deadline set for October 13, 2026. The lawsuit aims to address serious allegations regarding Aardvark's misleading statements and failure to disclose critical information pertaining to its product developments.

The Background of Aardvark Therapeutics

Aardvark Therapeutics, is a clinical-stage biopharmaceutical company focusing on developing innovative small-molecule therapies that target bitter taste receptors. The company has gained significant attention for its leading candidate, ARD-101, aimed at treating hyperphagia in Prader-Willi Syndrome (PWS). Unfortunately, recent events have sparked controversy and concern, leading to discussions about potential legal action among affected investors.

According to Hagens Berman Sobol Shapiro LLP, a prominent national shareholder rights law firm, investors who acquired Aardvark common stock through the company's Initial Public Offering (IPO) on February 13, 2025, or during the subsequent period up until May 14, 2026, find themselves entangled in a web of allegations centered around safety and efficacy misrepresentations related to ARD-101.

Allegations of Misleading Information

The pending class action lawsuit stems from claims that Aardvark Therapeutics, intentionally or unintentionally, failed to disclose material facts about ARD-101. Notably, it is alleged that:
1. ARD-101 was not as safe as the company had previously led investors to believe, raising questions about its viability as a treatment option.
2. Unexpected and reversible cardiac observations were documented during trials at doses exceeding target levels.
3. As a result, the prospects for Aardvark's clinical and regulatory advancements—specifically related to the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial—were significantly overstated, potentially misleading investors.

The consequences of these allegations began to unfold dramatically in early 2026. On February 27, Aardvark announced a voluntary pause of its Phase 3 HERO trial, citing safety monitoring findings. This announcement was a critical turning point, reportedly causing Aardvark's stock price to lose over 56% of its value in a single day. The situation worsened on May 14 when the FDA placed a full clinical hold on the investigational new drug application for ARD-101, further exacerbating investor losses as the stock plummeted another 32.1%.

What Affected Investors Can Do

For investors who suffered losses during this tumultuous period, now is the time to act. Hagens Berman urges affected parties to consider filing as Lead Plaintiff in the class action before the looming deadline of October 13, 2026. Those interested are encouraged to reach out to the firm to discuss their legal options and potential recovery paths, which could help align justice with accountability.

The firm also emphasizes its commitment to investigating the substance of these claims and ensuring a thorough examination of Aardvark's corporate communications and practices leading up to these unfortunate events.

Investors who may hold non-public insights regarding Aardvark Therapeutics are recommended to consider the SEC Whistleblower program, which provides financial incentives for information leading to successful recovery. Whistleblowers can receive rewards up to 30% of any SEC recovery related to these securities fraud allegations.

Conclusion

As Aardvark Therapeutics navigates these legal challenges, affected investors should remain vigilant and informed. Seeking legal counsel and staying proactive will be critical in these proceedings. The findings from this lawsuit will not only shape the future of Aardvark but also serve as a reminder of the importance of transparency in corporate governance.

With the October 13 deadline fast approaching, those impacted by Aardvark's actions have a narrow window to join the class action and potentially reclaim their lost investments.